A  ||| S:0 E:2 ||| DT
proliferation-inducing  ||| S:2 E:25 ||| JJ
ligand  ||| S:25 E:32 ||| NN
in  ||| S:32 E:35 ||| IN
atopic  ||| S:35 E:42 ||| JJ
dermatitis  ||| S:42 E:53 ||| NN
and  ||| S:53 E:57 ||| CC
vitiligo  ||| S:57 E:66 ||| VBG
A  ||| S:66 E:68 ||| DT
proliferation-inducing  ||| S:68 E:91 ||| JJ
ligand  ||| S:91 E:98 ||| NNS
( ||| S:98 E:99 ||| -LRB-
APRIL ||| S:99 E:104 ||| NNP
)  ||| S:104 E:106 ||| -RRB-
is  ||| S:106 E:109 ||| VBZ
a  ||| S:109 E:111 ||| DT
tumor  ||| S:111 E:117 ||| NN
necrosis  ||| S:117 E:126 ||| NN
factor  ||| S:126 E:133 ||| NN
( ||| S:133 E:134 ||| -LRB-
TNF ||| S:134 E:137 ||| NNP
)  ||| S:137 E:139 ||| -RRB-
superfamily  ||| S:139 E:151 ||| JJ
member  ||| S:151 E:158 ||| NN
ligand  ||| S:158 E:165 ||| NN
that  ||| S:165 E:170 ||| IN
stimulates  ||| S:170 E:181 ||| JJ
B cells  ||| S:181 E:189 ||| NN
in  ||| S:189 E:192 ||| IN
vitro  ||| S:192 E:198 ||| NN
and  ||| S:198 E:202 ||| CC
in  ||| S:202 E:205 ||| IN
vivo ||| S:205 E:209 ||| NN
.  ||| S:209 E:211 ||| .
It  ||| S:211 E:214 ||| PRP
also  ||| S:214 E:219 ||| RB
plays  ||| S:219 E:225 ||| VBZ
an  ||| S:225 E:228 ||| DT
important  ||| S:228 E:238 ||| JJ
role  ||| S:238 E:243 ||| NN
in  ||| S:243 E:246 ||| IN
T cell  ||| S:246 E:253 ||| CD
activation  ||| S:253 E:264 ||| NNS
and  ||| S:264 E:268 ||| CC
survival ||| S:268 E:276 ||| NN
.  ||| S:276 E:278 ||| .
This  ||| S:278 E:283 ||| DT
study  ||| S:283 E:289 ||| NN
was  ||| S:289 E:293 ||| VBD
conducted  ||| S:293 E:303 ||| VBN
to  ||| S:303 E:306 ||| TO
evaluate  ||| S:306 E:315 ||| VB
serum  ||| S:315 E:321 ||| JJ
levels  ||| S:321 E:328 ||| NNS
of  ||| S:328 E:331 ||| IN
APRIL  ||| S:331 E:337 ||| NNP
in  ||| S:337 E:340 ||| IN
patients  ||| S:340 E:349 ||| NNS
with  ||| S:349 E:354 ||| IN
atopic  ||| S:354 E:361 ||| JJ
dermatitis  ||| S:361 E:372 ||| NNS
( ||| S:372 E:373 ||| -LRB-
AD ||| S:373 E:375 ||| NNP
)  ||| S:375 E:377 ||| -RRB-
and  ||| S:377 E:381 ||| CC
vitiligo  ||| S:381 E:390 ||| NNS
and  ||| S:390 E:394 ||| CC
their  ||| S:394 E:400 ||| PRP$
correlation  ||| S:400 E:412 ||| NN
with  ||| S:412 E:417 ||| IN
disease  ||| S:417 E:425 ||| NN
activity ||| S:425 E:433 ||| NN
.  ||| S:433 E:435 ||| .
A  ||| S:435 E:437 ||| DT
total  ||| S:437 E:443 ||| NN
of  ||| S:443 E:446 ||| IN
100  ||| S:446 E:450 ||| CD
subjects  ||| S:450 E:459 ||| NNS
were  ||| S:459 E:464 ||| VBD
included ||| S:464 E:472 ||| VBN
;  ||| S:472 E:474 ||| :
these  ||| S:474 E:480 ||| DT
comprised  ||| S:480 E:490 ||| JJ
40  ||| S:490 E:493 ||| CD
AD  ||| S:493 E:496 ||| NN
patients ||| S:496 E:504 ||| NNS
,  ||| S:504 E:506 ||| ,
40  ||| S:506 E:509 ||| CD
vitiligo  ||| S:509 E:518 ||| CD
patients ||| S:518 E:526 ||| NNS
,  ||| S:526 E:528 ||| ,
and  ||| S:528 E:532 ||| CC
20  ||| S:532 E:535 ||| CD
control  ||| S:535 E:543 ||| NN
subjects ||| S:543 E:551 ||| NNS
.  ||| S:551 E:553 ||| .
Serum  ||| S:553 E:559 ||| NNP
APRIL  ||| S:559 E:565 ||| NNP
levels  ||| S:565 E:572 ||| NNS
were  ||| S:572 E:577 ||| VBD
measured  ||| S:577 E:586 ||| VBN
and  ||| S:586 E:590 ||| CC
their  ||| S:590 E:596 ||| PRP$
relationships  ||| S:596 E:610 ||| NNS
with  ||| S:610 E:615 ||| IN
the  ||| S:615 E:619 ||| DT
severity  ||| S:619 E:628 ||| NN
of  ||| S:628 E:631 ||| IN
AD  ||| S:631 E:634 ||| NNP
and  ||| S:634 E:638 ||| CC
activity  ||| S:638 E:647 ||| NN
of  ||| S:647 E:650 ||| IN
vitiligo  ||| S:650 E:659 ||| JJ
evaluated  ||| S:659 E:669 ||| NNS
according  ||| S:669 E:679 ||| VBG
to  ||| S:679 E:682 ||| TO
scores  ||| S:682 E:689 ||| NNS
on  ||| S:689 E:692 ||| IN
the  ||| S:692 E:696 ||| DT
SCORAD  ||| S:696 E:703 ||| NNP
( ||| S:703 E:704 ||| -LRB-
SCORing  ||| S:704 E:712 ||| JJ
of  ||| S:712 E:715 ||| IN
Atopic  ||| S:715 E:722 ||| NNP
Dermatitis ||| S:722 E:732 ||| NNP
)  ||| S:732 E:734 ||| -RRB-
and  ||| S:734 E:738 ||| CC
VIDA  ||| S:738 E:743 ||| NNP
( ||| S:743 E:744 ||| -LRB-
Vitiligo  ||| S:744 E:753 ||| NNP
Disease  ||| S:753 E:761 ||| NNP
Activity ||| S:761 E:769 ||| NNP
)  ||| S:769 E:771 ||| -RRB-
indices ||| S:771 E:778 ||| NNS
,  ||| S:778 E:780 ||| ,
respectively ||| S:780 E:792 ||| RB
.  ||| S:792 E:794 ||| .
The  ||| S:794 E:798 ||| DT
serum  ||| S:798 E:804 ||| JJ
level  ||| S:804 E:810 ||| NN
of  ||| S:810 E:813 ||| IN
APRIL  ||| S:813 E:819 ||| NNP
was  ||| S:819 E:823 ||| VBD
significantly  ||| S:823 E:837 ||| RB
higher  ||| S:837 E:844 ||| JJR
in  ||| S:844 E:847 ||| IN
AD  ||| S:847 E:850 ||| NNP
patients  ||| S:850 E:859 ||| NNS
than  ||| S:859 E:864 ||| IN
in  ||| S:864 E:867 ||| IN
the  ||| S:867 E:871 ||| DT
control  ||| S:871 E:879 ||| NN
group ||| S:879 E:884 ||| NN
.  ||| S:884 E:886 ||| .
Serum  ||| S:886 E:892 ||| NNP
APRIL  ||| S:892 E:898 ||| NNP
in  ||| S:898 E:901 ||| IN
patients  ||| S:901 E:910 ||| NNS
with  ||| S:910 E:915 ||| IN
severe  ||| S:915 E:922 ||| JJ
AD  ||| S:922 E:925 ||| NNP
showed  ||| S:925 E:932 ||| VBD
a  ||| S:932 E:934 ||| DT
statistically  ||| S:934 E:948 ||| JJ
significant  ||| S:948 E:960 ||| JJ
difference  ||| S:960 E:971 ||| NN
with  ||| S:971 E:976 ||| IN
serum  ||| S:976 E:982 ||| JJ
APRIL  ||| S:982 E:988 ||| NN
in  ||| S:988 E:991 ||| IN
patients  ||| S:991 E:1000 ||| NNS
with  ||| S:1000 E:1005 ||| IN
either  ||| S:1005 E:1012 ||| DT
mild  ||| S:1012 E:1017 ||| JJ
or  ||| S:1017 E:1020 ||| CC
moderate  ||| S:1020 E:1029 ||| JJ
AD ||| S:1029 E:1031 ||| NNP
.  ||| S:1031 E:1033 ||| .
Serum  ||| S:1033 E:1039 ||| NNP
APRIL  ||| S:1039 E:1045 ||| NNP
was  ||| S:1045 E:1049 ||| VBD
significantly  ||| S:1049 E:1063 ||| RB
higher  ||| S:1063 E:1070 ||| JJR
in  ||| S:1070 E:1073 ||| IN
vitiligo  ||| S:1073 E:1082 ||| JJ
patients  ||| S:1082 E:1091 ||| NNS
than  ||| S:1091 E:1096 ||| IN
in  ||| S:1096 E:1099 ||| IN
the  ||| S:1099 E:1103 ||| DT
control  ||| S:1103 E:1111 ||| NN
group ||| S:1111 E:1116 ||| NN
.  ||| S:1116 E:1118 ||| .
Differences  ||| S:1118 E:1130 ||| NNS
in  ||| S:1130 E:1133 ||| IN
serum  ||| S:1133 E:1139 ||| JJ
APRIL  ||| S:1139 E:1145 ||| NN
among  ||| S:1145 E:1151 ||| IN
patients  ||| S:1151 E:1160 ||| NNS
with  ||| S:1160 E:1165 ||| IN
different  ||| S:1165 E:1175 ||| JJ
VIDA  ||| S:1175 E:1180 ||| NN
scores  ||| S:1180 E:1187 ||| NNS
were  ||| S:1187 E:1192 ||| VBD
significant  ||| S:1192 E:1204 ||| JJ
only  ||| S:1204 E:1209 ||| JJ
between  ||| S:1209 E:1217 ||| IN
patients  ||| S:1217 E:1226 ||| NNS
with  ||| S:1226 E:1231 ||| IN
VIDA  ||| S:1231 E:1236 ||| NNP
scores  ||| S:1236 E:1243 ||| NNS
of  ||| S:1243 E:1246 ||| IN
+1  ||| S:1246 E:1249 ||| NNP
and  ||| S:1249 E:1253 ||| CC
+4 ||| S:1253 E:1255 ||| NNP
.  ||| S:1255 E:1257 ||| .
Statistically  ||| S:1257 E:1271 ||| RB
significant  ||| S:1271 E:1283 ||| JJ
positive  ||| S:1283 E:1292 ||| JJ
correlations  ||| S:1292 E:1305 ||| NN
emerged  ||| S:1305 E:1313 ||| VBD
between  ||| S:1313 E:1321 ||| IN
serum  ||| S:1321 E:1327 ||| JJ
APRIL  ||| S:1327 E:1333 ||| NNP
and  ||| S:1333 E:1337 ||| CC
activity  ||| S:1337 E:1346 ||| NN
of  ||| S:1346 E:1349 ||| IN
AD  ||| S:1349 E:1352 ||| NNP
( ||| S:1352 E:1353 ||| -LRB-
r = 0.939 ||| S:1353 E:1362 ||| NNP
)  ||| S:1362 E:1364 ||| -RRB-
and  ||| S:1364 E:1368 ||| CC
vitiligo  ||| S:1368 E:1377 ||| NNS
( ||| S:1377 E:1378 ||| -LRB-
r = 0.740 ||| S:1378 E:1387 ||| NNP
) ||| S:1387 E:1388 ||| -RRB-
.  ||| S:1388 E:1390 ||| .
APRIL  ||| S:1390 E:1396 ||| NNP
may  ||| S:1396 E:1400 ||| MD
play  ||| S:1400 E:1405 ||| VB
a  ||| S:1405 E:1407 ||| DT
role  ||| S:1407 E:1412 ||| NN
in  ||| S:1412 E:1415 ||| IN
the  ||| S:1415 E:1419 ||| DT
pathogeneses  ||| S:1419 E:1432 ||| NN
of  ||| S:1432 E:1435 ||| IN
AD  ||| S:1435 E:1438 ||| NNP
and  ||| S:1438 E:1442 ||| CC
vitiligo  ||| S:1442 E:1451 ||| NNS
and  ||| S:1451 E:1455 ||| CC
could  ||| S:1455 E:1461 ||| MD
be  ||| S:1461 E:1464 ||| VB
used  ||| S:1464 E:1469 ||| VBN
as  ||| S:1469 E:1472 ||| IN
an  ||| S:1472 E:1475 ||| DT
objective  ||| S:1475 E:1485 ||| JJ
marker  ||| S:1485 E:1492 ||| NN
for  ||| S:1492 E:1496 ||| IN
the  ||| S:1496 E:1500 ||| DT
assessment  ||| S:1500 E:1511 ||| NN
of  ||| S:1511 E:1514 ||| IN
AD  ||| S:1514 E:1517 ||| NNP
severity  ||| S:1517 E:1526 ||| NN
and  ||| S:1526 E:1530 ||| CC
vitiligo  ||| S:1530 E:1539 ||| JJ
activity ||| S:1539 E:1547 ||| NN
.  ||| S:1547 E:1549 ||| .
Further  ||| S:1549 E:1557 ||| JJ
studies  ||| S:1557 E:1565 ||| NNS
are  ||| S:1565 E:1569 ||| VBP
required  ||| S:1569 E:1578 ||| VBN
to  ||| S:1578 E:1581 ||| TO
clarify  ||| S:1581 E:1589 ||| VB
the  ||| S:1589 E:1593 ||| DT
precise  ||| S:1593 E:1601 ||| JJ
mechanism  ||| S:1601 E:1611 ||| NN
of  ||| S:1611 E:1614 ||| IN
APRIL  ||| S:1614 E:1620 ||| NNP
in  ||| S:1620 E:1623 ||| IN
the  ||| S:1623 E:1627 ||| DT
pathogeneses  ||| S:1627 E:1640 ||| NN
of  ||| S:1640 E:1643 ||| IN
AD  ||| S:1643 E:1646 ||| NNP
and  ||| S:1646 E:1650 ||| CC
vitiligo  ||| S:1650 E:1659 ||| NNS
and  ||| S:1659 E:1663 ||| CC
to  ||| S:1663 E:1666 ||| TO
test  ||| S:1666 E:1671 ||| VB
the  ||| S:1671 E:1675 ||| DT
possible  ||| S:1675 E:1684 ||| JJ
use  ||| S:1684 E:1688 ||| NN
of  ||| S:1688 E:1691 ||| IN
APRIL  ||| S:1691 E:1697 ||| NNP
inhibitors  ||| S:1697 E:1708 ||| NN
as  ||| S:1708 E:1711 ||| IN
novel  ||| S:1711 E:1717 ||| NN
modalities  ||| S:1717 E:1728 ||| NN
of  ||| S:1728 E:1731 ||| IN
therapy ||| S:1731 E:1738 ||| NN
.  ||| S:1738 E:1740 ||| .
